Cost Reductions And New Partnerships Will Shape Profit Prospects By 2026

Analysts have raised their price target for Ginkgo Bioworks shares from $6 to $9, citing stronger-than-expected second quarter results and improved cost controls. However, they caution that visibility into long-term growth and EBITDA profitability remains limited.

Analysts have raised their price target for Ginkgo Bioworks Holdings from $6 to $9, citing a significant revenue beat in the second quarter and faster-than-anticipated cost reductions. However, they still note some uncertainty about profitability targets for 2026.

Analysts have raised their price target for Ginkgo Bioworks Holdings from $11.33 to $12.00 per share, citing a notable Q2 topline beat and improved cost management as key drivers for the revised outlook. Analyst Commentary Following the recent performance and guidance update, analyst opinions on Ginkgo Bioworks Holdings remain mixed, reflecting both the company’s progress and outstanding challenges.

Analysts have raised Ginkgo Bioworks Holdings’ price target to $11.33 on the back of a strong Q2 topline beat and accelerated cost reductions, though concerns persist over EBITDA breakeven achievability and medium-term growth visibility. Analyst Commentary Bullish analysts highlight a significant Q2 topline beat driven by faster-than-expected cost reductions.

The notable increase in Ginkgo Bioworks' consensus price target reflects significantly improved net profit margins and a marked decline in future P/E, resulting in a fair value revision from $8.67 to $10.33. What's in the News Ginkgo Bioworks reaffirmed its full-year 2025 revenue guidance at $167 million to $187 million.

Despite a substantial downgrade in consensus revenue growth forecasts and a significantly higher future P/E multiple, the consensus analyst price target for Ginkgo Bioworks Holdings has increased from $7.95 to $8.67. What's in the News Ginkgo Bioworks was selected by the U.S. DOE's Environmental Molecular Sciences Laboratory to deliver a $4.66M automated phenotyping platform, integrating advanced automation and AI-driven workflows.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased revenue growth from 0.4% to -0.0%.

AnalystConsensusTarget has increased revenue growth from -5.6% to 0.4%, decreased future PE multiple from 44.7x to 33.3x, increased discount rate from 8.9% to 9.9% and decreased shares outstanding growth rate from 0.1% to -0.0%.